FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/YnbisOzf0L https://t.co/9AyxEBpasb

Ph 3 360 pt RCT of sarilumab in #GCA was terminated early (COVID). 83 pts Rx'd, only 35%(29) completed. Sustained remission @wk 52: - SAR 200: 6/13 - SAR 150: 3/7 - PBO: 0/6 All had 26wk GC taper Sm sample size & COVID ruined RCT interpretation https://t.co/axOvJGpUti #PMR https://t.co/Xpabxn1IjZ

Subcutaneous Biosimilars? Dr. Cush reviews RheumNow's top entries the #PMR Campaign, news, journal reports and regulatory actions. https://t.co/BkKFbv0I64 https://t.co/EABeZxCKYZ

Analysis of the NOR-DMARD registry and Vienna #RA cohorts provided novel definitions for an RA flare, requiring an increase of -4.7 on the SDAI or -4.5 on the CDAI Flare definitions correlated with functional and Xray outcomes. https://t.co/f2G2nYyyWT https://t.co/JczDZa9oUf

JAMA Review of Knee Pain: - 5% PCP visits for knee pain: - Knee #OA: 654 mill worldwide, mostly >45 yrs age - Patellofemoral OA: < 40 yrs age; Sx: ant knee pain w/ squat - Meniscal tears: 12% adults < 40 yrs; dx by McMurray test & joint line tenderness https://t.co/kf1OOiwIR4 https://t.co/e5hiodDZgn

New download available--#PMR Survey Results https://t.co/rfOQxFrO3I https://t.co/l8T7P3tdOb

#PMR Mythbusters: PMR Needs Elevated ESR or CRP https://t.co/GbHSyu24qw https://t.co/yaRa0UIQq1

Anti-Phospholipid Antibodies - Infrequent in Certain Groups Among patients with SLE, high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found. https://t.co/qQygcS3Ktw https://t.co/FVKlvFuuFn

#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/g6xIzsxjkr https://t.co/qQnouc5DPm

ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily. https://t.co/uTDBmRvCV5 https://t.co/Qx6fZSTeS5

Universal Imaging for GCA in #PMR? Not So Fast https://t.co/p581kXSzAb https://t.co/UIQjCxAzym